Victory Capital Management Inc. Buys 35,732 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 11.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 339,331 shares of the company’s stock after purchasing an additional 35,732 shares during the quarter. Victory Capital Management Inc. owned approximately 1.32% of Krystal Biotech worth $26,882,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Arizona State Retirement System raised its holdings in Krystal Biotech by 3.3% in the 3rd quarter. Arizona State Retirement System now owns 4,876 shares of the company’s stock worth $340,000 after purchasing an additional 158 shares during the period. ProShare Advisors LLC raised its holdings in Krystal Biotech by 3.7% in the 3rd quarter. ProShare Advisors LLC now owns 4,511 shares of the company’s stock worth $315,000 after purchasing an additional 161 shares during the period. Principal Financial Group Inc. increased its stake in Krystal Biotech by 4.9% in the 4th quarter. Principal Financial Group Inc. now owns 5,653 shares of the company’s stock worth $448,000 after buying an additional 264 shares in the last quarter. Handelsbanken Fonder AB increased its stake in Krystal Biotech by 0.3% in the 4th quarter. Handelsbanken Fonder AB now owns 105,200 shares of the company’s stock worth $8,334,000 after buying an additional 300 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in Krystal Biotech by 51.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock worth $72,000 after buying an additional 346 shares in the last quarter. 80.80% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $96.06 on Friday. The company has a 50 day simple moving average of $83.20 and a 200-day simple moving average of $79.82. Krystal Biotech, Inc. has a 1 year low of $49.17 and a 1 year high of $97.31.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its quarterly earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.01. On average, analysts anticipate that Krystal Biotech, Inc. will post -5.85 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, Director Daniel Janney sold 7,900 shares of the firm’s stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $90.32, for a total transaction of $713,528.00. Following the completion of the sale, the director now owns 224,462 shares in the company, valued at approximately $20,273,407.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Daniel Janney sold 7,900 shares of the stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $90.32, for a total transaction of $713,528.00. Following the completion of the transaction, the director now owns 224,462 shares of the company’s stock, valued at approximately $20,273,407.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $87.65, for a total transaction of $2,191,250.00. Following the transaction, the insider now directly owns 1,649,206 shares of the company’s stock, valued at approximately $144,552,905.90. The disclosure for this sale can be found here. Insiders sold 90,000 shares of company stock worth $7,786,432 in the last 90 days. Insiders own 17.00% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of analyst reports. Stifel Nicolaus initiated coverage on Krystal Biotech in a research note on Monday, April 17th. They issued a “buy” rating and a $102.00 price target for the company. Chardan Capital reiterated a “buy” rating and issued a $133.00 price target on shares of Krystal Biotech in a research note on Tuesday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $119.00 price target on shares of Krystal Biotech in a research note on Tuesday, February 28th. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Wednesday, March 22nd. Finally, Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Krystal Biotech in a research note on Tuesday, February 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $115.80.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.